Price
Target price
€50.50
€50.50
6.090%
2.9
6.090%
€84.74
22.08.24 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
A very strong showing by Ultragenyx Pharmaceutical Inc. today, with an increase of €2.90 (6.090%) compared to yesterday's price.
The stock is one of the favorites of our community with 25 Buy predictions and 1 Sell predictions.
As a result the target price of 84 € shows a very positive potential of 66.34% compared to the current price of 50.5 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 6.090% | 7.447% | 20.813% | 52.108% | 16.359% | -26.277% | 0.578% |
| Ironwood Pharmaceuticals | -5.380% | 7.653% | -33.016% | -50.059% | -58.627% | -61.982% | -45.351% |
| Arrowhead Pharmaceuticals Inc. | 0.730% | 7.427% | -16.554% | -15.983% | -21.413% | -58.166% | -20.180% |
| Novocure Ltd | 0.650% | -0.770% | -6.881% | -41.606% | 12.820% | -86.008% | -80.601% |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Barclays PLC from $83.00 to $81.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wells Fargo & Company from $72.00 to $75.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $67.00 to $76.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
